Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Cemiplimab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Senhwa Biosciences' Pidnarulex Partners with Global PD-1 Leaders
    Senhwa Biosciences' Pidnarulex Partners with Global PD-1 Leaders

    16 Sep 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/diagnostic-center/senhwa-biosciences-pidnarulex-joins-forces-with-global-pd-1-leaders-to-advance-next-gen-immunotherapy-17800

    INDPHARMAPOST
    16 Sep 2025
    Share Share
    Sanofi's Libtayo Combo Shows 5-Year Survival Gain in NSCLC
    Sanofi's Libtayo Combo Shows 5-Year Survival Gain in NSCLC

    16 Sep 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/diagnostic-center/libtayo-plus-chemotherapy-demonstrates-five-year-survival-benefit-in-advanced-nsclc-17810

    INDPHARMAPOST
    16 Sep 2025
    Share Share
    MAIA Bio Reveals Positive THIO-101 Phase 2 Data in Lung Cancer
    MAIA Bio Reveals Positive THIO-101 Phase 2 Data in Lung Cancer

    11 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/11/3148625/0/en/MAIA-Biotechnology-Highlights-Positive-Efficacy-Data-from-THIO-101-Phase-2-Clinical-Trial-in-Non-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    11 Sep 2025
    Share Share
    Libtayo Plus Chemo Shows 5-Year Survival in Advanced Lung Cancer
    Libtayo Plus Chemo Shows 5-Year Survival in Advanced Lung Cancer

    09 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/09/3146733/0/en/Libtayo-cemiplimab-Plus-Chemotherapy-Results-at-Five-Years-Reinforce-Significant-and-Durable-Improvements-in-Survival-Outcomes-for-Advanced-Non-small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    09 Sep 2025
    Share Share
    MAIA Biotech's Abstract Chosen for Poster at IASLC Conference
    MAIA Biotech's Abstract Chosen for Poster at IASLC Conference

    05 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/05/3145282/0/en/MAIA-Biotechnology-Abstract-Selected-for-Poster-Presentation-at-2025-IASLC-World-Conference-on-Lung-Cancer.html

    GLOBENEWSWIRE
    05 Sep 2025
    Share Share
    Libtayo Phase 3 Data in Adjuvant Treatment of High-Risk Carcinoma
    Libtayo Phase 3 Data in Adjuvant Treatment of High-Risk Carcinoma

    31 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/31/3091406/0/en/Libtayo-cemiplimab-Phase-3-Data-in-the-Adjuvant-Treatment-of-Post-Surgical-High-Risk-Cutaneous-Squamous-Cell-Carcinoma-CSCC-Have-Potential-to-Be-Practice-Changing.html

    GLOBENEWSWIRE
    31 May 2025
    Share Share